Our technology, called NEXT (Nonsurgical EXogenous crosslink Therapy) is a chemically made device formed following injection of a crosslinking agent into the lesion of the tendon or ligament, where it immediately interacts with the native proteins (collagen) causing the tendon tissue to strengthen and stabilize. Additionally our technology can treat surgery closures, wound care, and other collagen tissue based injuries.
| Website | https://www.equinext.net |
| Revenue | $1 million |
| Funding | $685000 |
| Employees | 2 (0 on RocketReach) |
| Founded | 2010 |
| Address | 1501 Bull Lea Rd, Ste 103, Lexington, Kentucky 40511, US |
| Phone | +1 502-419-8099 |
| Industry | Medical Devices, Biotechnology, Pharmaceuticals, Healthcare |
| Keywords | Orthopedic Technology, Regenerative Medicine, Tissue Repair, Non Invasive Therapy, Biological Therapy, Tissue Regeneration, Musculoskeletal Health, Biomedical Devices, Therapeutic Devices, Sports Medicine, Medical Devices |
| Competitors | Accenture, TEKsystems, Insight Global, Randstad USA, Apex Systems, Toptal, Experis, K Force, Modis, Cognizant Softvision +39 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 80 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies |
Looking for a particular Equinext employee's phone or email?
Equinext Questions
The Equinext annual revenue was $1 million in 2026.
Equinext is based in Lexington, Kentucky.
The NAICS codes for Equinext are [325, 3254, 32].
The SIC codes for Equinext are [283, 80, 28].
Related Companies
